Vaxart Announces Topline Data From The Phase 2 Challenge Study Of Its Monovalent Norovirus Vaccine Candidate; Study Met 5 Of 6 Primary Endpoints; Vaccine Was Safe And Well Tolerated With No Vaccine-related Serious Adverse Events
Portfolio Pulse from Happy Mohamed
Vaxart, Inc. (NASDAQ:VXRT) has announced top-line data from the Phase 2 challenge study of its oral tablet monovalent norovirus vaccine candidate. The study met 5 of 6 primary endpoints, showing the vaccine to be safe and well tolerated with no serious adverse events. The vaccine led to a statistically significant reduction in infection rate and a substantial reduction in viral shedding. However, it did not achieve a statistically significant reduction in norovirus acute gastroenteritis.
September 06, 2023 | 8:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vaxart's Phase 2 study results for its norovirus vaccine candidate are largely positive, meeting 5 of 6 primary endpoints. This could potentially boost investor confidence in the company's vaccine development capabilities.
The positive results from the Phase 2 study of Vaxart's norovirus vaccine candidate indicate the company's strong capabilities in vaccine development. This could potentially attract more investors, leading to a rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100